Nkarta, Inc.
Develops allogeneic, off-the-shelf natural killer (NK) cell therapies.
NKTX | US
Overview
Corporate Details
- ISIN(s):
- US65487U1088
- LEI:
- Country:
- United States of America
- Address:
- 1150 VETERANS BOULEVARD, 94080 SOUTH SAN FRANCISCO
- Website:
- https://www.nkartatx.com/
- Sector:
- Manufacturing
Description
Nkarta, Inc. is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies. The company's proprietary technology is designed to engineer NK cells to target and eliminate dysfunctional or diseased cells. Nkarta's primary focus is on developing treatments for B cell-mediated autoimmune diseases, with clinical programs investigating therapies for conditions such as lupus nephritis. The company's platform also has applications in oncology. Nkarta aims to provide accessible cell therapies that can reset a disordered immune system and offer new therapeutic options for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Nkarta, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Nkarta, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Nkarta, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
